Valneva SE
VALN
View Detailed Chart
8.485USD
+0.125+1.50%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
1.38BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+1.50%
5 Days
+2.97%
1 Month
-3.80%
6 Months
+51.52%
Year to Date
+94.08%
1 Year
+102.51%
View Detailed Chart
TradingKey Stock Score of Valneva SE
Currency: USD Updated: 2025-12-24Key Insights
Valneva SE's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 114/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 12.89.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Valneva SE's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
4
analysts
Buy
Current Rating
12.887
Target Price
+44.48%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Valneva SE Highlights
StrengthsRisks
Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
Overvalued
The company’s latest PE is -7.66, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 4.53M shares, increasing 44.31% quarter-over-quarter.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 3.26.
Valneva SE News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Valneva SE Info
Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
Ticker SymbolVALN
CompanyValneva SE
CEOLingelbach (Thomas)
Websitehttps://valneva.com/
FAQs
What is the current price of Valneva SE (VALN)?
The current price of Valneva SE (VALN) is 8.485.
What is the symbol of Valneva SE?
The ticker symbol of Valneva SE is VALN.
What is the 52-week high of Valneva SE?
The 52-week high of Valneva SE is 12.250.
What is the 52-week low of Valneva SE?
The 52-week low of Valneva SE is 4.021.
What is the market capitalization of Valneva SE?
The market capitalization of Valneva SE is 1.38B.
What is the net income of Valneva SE?
The net income of Valneva SE is -12.25M.
Is Valneva SE (VALN) currently rated as Buy, Hold, or Sell?
According to analysts, Valneva SE (VALN) has an overall rating of Buy, with a price target of 12.887.
What is the Earnings Per Share (EPS TTM) of Valneva SE (VALN)?
The Earnings Per Share (EPS TTM) of Valneva SE (VALN) is -1.108.
Related Instruments
+0.41%
+0.94%
+0.51%
+0.34%
-0.17%
+1.42%
+0.75%
+1.80%
+0.38%
+0.66%
+0.08%
+0.82%
+0.81%
+0.08%
+0.23%
-0.05%
-0.19%
0.00%
+1.54%
+0.50%
